FDA Approves Padcev-Keytruda Combo for Bladder Cancer, Expanding Label
PFE is trading near its 52-week low of $23.11 (4.9% above the low) on light trading volume (0.2× avg).
Summary
The FDA approved Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) as neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer, regardless of cisplatin eligibility. This expands the combination's use beyond the previously approved metastatic setting, opening a larger patient population. The approval follows positive Phase 3 data and strengthens Pfizer's oncology portfolio at a time when the stock trades near 52-week lows. The label expansion could drive meaningful revenue growth for both drugs, which are already key growth drivers. No specific sales estimates were provided, but the broader indication significantly increases the addressable market.
At the time of this announcement, PFE was trading at $24.24 on NYSE in the Life Sciences sector, with a market capitalization of approximately $138.1B. The 52-week trading range was $23.11 to $28.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.